{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T04:07:22Z","timestamp":1776744442513,"version":"3.51.2"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,4,7]],"date-time":"2018-04-07T00:00:00Z","timestamp":1523059200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Psychiatry Rep"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s11920-018-0899-6","type":"journal-article","created":{"date-parts":[[2018,4,7]],"date-time":"2018-04-07T05:36:48Z","timestamp":1523079408000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Advances in Pharmacotherapy of Late-Life Depression"],"prefix":"10.1007","volume":"20","author":[{"given":"John L.","family":"Beyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim G.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,7]]},"reference":[{"key":"899_CR1","doi-asserted-by":"crossref","unstructured":"Diniz BS, Butters MA, Albert SM, Dew MA, Reynolds CF 3rd. Late-life depression and risk of vascular dementia and Alzheimer\u2019s disease: systematic review and meta-analysis of community-based cohort studies. Br J Psychiatry. 2013;202(5):329\u201335.","DOI":"10.1192\/bjp.bp.112.118307"},{"issue":"5","key":"899_CR2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1001\/archgenpsychiatry.2011.1481","volume":"69","author":"DE Barnes","year":"2012","unstructured":"Barnes DE, Yaffe K, Byers AL, McCormick M, Schaefer C, Whitmer RA. Midlife vs late-life depressive symptoms and risk of dementia: differential effects for Alzheimer disease and vascular dementia. Arch Gen Psychiatry. 2012;69(5):493\u20138.","journal-title":"Arch Gen Psychiatry"},{"key":"899_CR3","doi-asserted-by":"crossref","unstructured":"Zhang Y, Chen Y, Ma L. Depression and cardiovascular disease in elderly: current understanding. J. Clin. Neurosci. 2017;","DOI":"10.1016\/j.jocn.2017.09.022"},{"issue":"20","key":"899_CR4","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1001\/jama.1997.03540440052032","volume":"277","author":"J Unutzer","year":"1997","unstructured":"Unutzer J, Patrick DL, Simon G, et al. Depressive symptoms and the cost of health services in HMO patients aged 65 years and older. A 4-year prospective study. JAMA. 1997;277(20):1618\u201323.","journal-title":"JAMA"},{"issue":"3","key":"899_CR5","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/j.1532-5415.2008.02134.x","volume":"57","author":"J Unutzer","year":"2009","unstructured":"Unutzer J, Schoenbaum M, Katon WJ, et al. Healthcare costs associated with depression in medically ill fee-for-service medicare participants. J Am Geriatr Soc. 2009;57(3):506\u201310.","journal-title":"J Am Geriatr Soc"},{"key":"899_CR6","doi-asserted-by":"crossref","unstructured":"Miller MD, Frank E, Cornes C, Houck PR, Reynolds CF 3rd. The value of maintenance interpersonal psychotherapy (IPT) in older adults with different IPT foci. Am J Geriatr Psychiatry. 2003;11(1):97\u2013102.","DOI":"10.1097\/00019442-200301000-00013"},{"issue":"10","key":"899_CR7","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1111\/j.1532-5415.2012.04166.x","volume":"60","author":"RL Gould","year":"2012","unstructured":"Gould RL, Coulson MC, Howard RJ. Cognitive behavioral therapy for depression in older people: a meta-analysis and meta-regression of randomized controlled trials. J Am Geriatr Soc. 2012;60(10):1817\u201330.","journal-title":"J Am Geriatr Soc"},{"key":"899_CR8","first-page":"CD004853","volume":"1","author":"KC Wilson","year":"2008","unstructured":"Wilson KC, Mottram PG, Vassilas CA. Psychotherapeutic treatments for older depressed people. Cochrane Database Syst Rev. 2008;1:CD004853.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"899_CR9","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1176\/appi.ajp.2012.12070927","volume":"170","author":"JC Nelson","year":"2013","unstructured":"Nelson JC, Delucchi KL, Schneider LS. Moderators of outcome in late-life depression: a patient-level meta-analysis. Am J Psychiatry. 2013;170(6):651\u20139.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"899_CR10","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/01.jcp.0000155819.67209.e5","volume":"25","author":"PS Wang","year":"2005","unstructured":"Wang PS, Schneeweiss S, Brookhart MA, Glynn RJ, Mogun H, Patrick AR, et al. Suboptimal antidepressant use in the elderly. J Clin Psychopharmacol. 2005;25(2):118\u201326.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"899_CR11","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.jad.2011.09.038","volume":"136","author":"LC Barry","year":"2012","unstructured":"Barry LC, Abou JJ, Simen AA, Gill TM. Under-treatment of depression in older persons. J Affect Disord. 2012;136(3):789\u201396.","journal-title":"J Affect Disord"},{"issue":"3","key":"899_CR12","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/phar.1898","volume":"37","author":"V Bali","year":"2017","unstructured":"\u2022 Bali V, Chatterjee S, Johnson ML, Chen H, Carnahan RM, Aparasu RR. Risk of mortality in elderly nursing home patients with depression using paroxetine. Pharmacotherapy. 2017;37(3):287\u201396. This study shows there is no increased risk of mortality with use of paroxetine in nursing home patients.","journal-title":"Pharmacotherapy"},{"issue":"12","key":"899_CR13","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1176\/appi.ps.201500011","volume":"66","author":"V Bali","year":"2015","unstructured":"\u2022 Bali V, Chatterjee S, Carnahan RM, Chen H, Johnson ML, Aparasu RR. Risk of dementia among elderly nursing home patients using paroxetine and other selective serotonin reuptake inhibitors. Psychiatr Serv. 2015;66(12):1333\u201340. This study shows there is no increased risk of dementia with use of paroxetine in nursing home patients.","journal-title":"Psychiatr Serv"},{"issue":"8","key":"899_CR14","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1177\/1533317516673463","volume":"31","author":"V Bali","year":"2016","unstructured":"\u2022 Bali V, Chatterjee S, Johnson ML, Chen H, Carnahan RM, Aparasu RR. Risk of cognitive decline associated with paroxetine use in elderly nursing home patients with depression. Am J Alzheimers Dis Other Demen. 2016;31(8):678\u201386. This study shows there is no increased risk of cognitive decline with use of paroxetine in nursing home patients","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"1","key":"899_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/JGP.0b013e3181591c09","volume":"16","author":"A Bose","year":"2008","unstructured":"Bose A, Li D, Gandhi C. Escitalopram in the acute treatment of depressed patients aged 60 years or older. Am J Geriatr Psychiatry. 2008;16(1):14\u201320.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"5","key":"899_CR16","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1177\/147323001103900540","volume":"39","author":"YM Chen","year":"2011","unstructured":"Chen YM, Huang XM, Thompson R, Zhao YB. Clinical features and efficacy of escitalopram treatment for geriatric depression. J Int Med Res. 2011;39(5):1946\u201353.","journal-title":"J Int Med Res"},{"issue":"12","key":"899_CR17","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1176\/appi.ps.201400480","volume":"66","author":"CA Hall","year":"2015","unstructured":"Hall CA, Simon KM, Lenze EJ, Dew MA, Begley A, Butters MA, et al. Depression remission rates among older black and white adults: analyses from the IRL-GREY trial. Psychiatr Serv. 2015;66(12):1303\u201311.","journal-title":"Psychiatr Serv"},{"issue":"3","key":"899_CR18","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/JCP.0b013e3181dcb594","volume":"30","author":"SG Kornstein","year":"2010","unstructured":"Kornstein SG, Clayton AH, Soares CN, Padmanabhan SK, Guico-Pabia CJ. Analysis by age and sex of efficacy data from placebo-controlled trials of desvenlafaxine in outpatients with major depressive disorder. J Clin Psychopharmacol. 2010;30(3):294\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"899_CR19","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1089\/jwh.2014.4900","volume":"24","author":"SG Kornstein","year":"2015","unstructured":"Kornstein SG, Clayton AH, Bao W, Guico-Pabia CJ. A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women. Journal of women's health (2002). 2015;24(4):281\u201390.","journal-title":"Journal of women's health (2002)"},{"issue":"6","key":"899_CR20","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1176\/ajp.2007.164.6.900","volume":"164","author":"J Raskin","year":"2007","unstructured":"Raskin J, Wiltse CG, Siegal A, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry. 2007;164(6):900\u20139.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"899_CR21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jagp.2013.01.019","volume":"22","author":"M Robinson","year":"2014","unstructured":"\u2022\u2022 Robinson M, Oakes TM, Raskin J, Liu P, Shoemaker S, Nelson JC. Acute and long-term treatment of late-life major depressive disorder: duloxetine versus placebo. Am J Geriatr Psychiatry. 2014;22(1):34\u201345. This study shows no increased efficacy for treatment of depression of duloxetine over placebo for the primary endpoint at 12 weeks but it did separate from placebo at weeks 4,8,16 and 20 weeks. There was also a significant beneficial effect on pain at all weeks of the study.","journal-title":"Am J Geriatr Psychiatry"},{"key":"899_CR22","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Kerner N, D\u2019Antonio K, Pelton GH, et al. An open treatment trial of duloxetine in elderly patients with dysthymic disorder. SAGE open medicine. 2014;2. Duloxetine decreased dythymic symptoms and somatic symptoms in the geriatric population.","DOI":"10.1177\/2050312114533536"},{"issue":"4","key":"899_CR23","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1177\/0269881108100254","volume":"24","author":"K Hewett","year":"2010","unstructured":"Hewett K, Chrzanowski W, Jokinen R, Felgentreff R, Shrivastava RK, Gee MD, et al. Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder. Journal of psychopharmacology (Oxford, England). 2010;24(4):521\u20139.","journal-title":"Journal of psychopharmacology (Oxford, England)"},{"issue":"11","key":"899_CR24","doi-asserted-by":"publisher","first-page":"e1291","DOI":"10.4088\/JCP.14m08992","volume":"75","author":"HA Croft","year":"2014","unstructured":"Croft HA, Pomara N, Gommoll C, Chen D, Nunez R, Mathews M. Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry. 2014;75(11):e1291\u20138.","journal-title":"J. Clin. Psychiatry."},{"issue":"4","key":"899_CR25","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/YIC.0b013e3283542457","volume":"27","author":"C Katona","year":"2012","unstructured":"Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012;27(4):215\u201323.","journal-title":"Int Clin Psychopharmacol"},{"issue":"11","key":"899_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.17116\/jnevro201511511155-62","volume":"115","author":"YB Kalyn","year":"2015","unstructured":"Kalyn YB, Safarova TP, Yakovleva OB, Sheshenin VS, Kornilov VV, Shipilova ES, et al. Experience of the antidepressive therapy with valdoxan (agomelatine) in a psychogeriatric unit of the psychiatric hospital. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(11):55\u201362.","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"issue":"6","key":"899_CR27","doi-asserted-by":"publisher","first-page":"587","DOI":"10.4088\/JCP.12m08250","volume":"74","author":"R Heun","year":"2013","unstructured":"Heun R, Ahokas A, Boyer P, Gimenez-Montesinos N, Pontes-Soares F, Olivier V. The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study. J. Clin. Psychiatry. 2013;74(6):587\u201394.","journal-title":"J. Clin. Psychiatry."},{"issue":"8","key":"899_CR28","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.jagp.2013.01.010","volume":"21","author":"H Katila","year":"2013","unstructured":"\u2022\u2022 Katila H, Mezhebovsky I, Mulroy A, Berggren L, Eriksson H, Earley W, et al. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder. Am J Geriatr Psychiatry. 2013;21(8):769\u201384. This study showed quetiapine has efficacy in geriatric depression especially for patients with sleep disturbances.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"12","key":"899_CR29","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1002\/gps.2483","volume":"25","author":"DP Seitz","year":"2010","unstructured":"Seitz DP, Gill SS, Conn DK. Citalopram versus other antidepressants for late-life depression: a systematic review and meta-analysis. Int. J. Geriatr. Psychiatry. 2010;25(12):1296\u2013305.","journal-title":"Int. J. Geriatr. Psychiatry."},{"issue":"5","key":"899_CR30","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1111\/jgs.13395","volume":"63","author":"K Thorlund","year":"2015","unstructured":"\u2022\u2022 Thorlund K, Druyts E, Wu P, Balijepalli C, Keohane D, Mills E. Comparative efficacy and safety of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors in older adults: a network meta-analysis. J Am Geriatr Soc. 2015;63(5):1002\u20139. This review shows that sertraline, paroxetine and duloxetine are superior to placebo among the SSRI and SNRI's.","journal-title":"J Am Geriatr Soc"},{"issue":"10011","key":"899_CR31","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/S0140-6736(15)00308-6","volume":"386","author":"EJ Lenze","year":"2015","unstructured":"\u2022\u2022 Lenze EJ, Mulsant BH, Blumberger DM, Karp JF, Newcomer JW, Anderson SJ, et al. Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(10011):2404\u201312. Aripiprazole is a safe and effective augmentation to venlafaxine for treatment resistant depression. Side effects include akithisia and parkinsonism.","journal-title":"Lancet"},{"issue":"6","key":"899_CR32","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1176\/appi.ajp.2014.14070889","volume":"172","author":"H Lavretsky","year":"2015","unstructured":"\u2022\u2022 Lavretsky H, Reinlieb M, St Cyr N, Siddarth P, Ercoli LM, Senturk D. Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015;172(6):561\u20139. The citalopram plus methylphenidate group showed the highest improvement in depression severity and faster treatment response than citalopram plus placebo and methylphendate plus placebo.","journal-title":"Am J Psychiatry"},{"issue":"6","key":"899_CR33","first-page":"525","volume":"19","author":"V Omranifard","year":"2014","unstructured":"\u2022 Omranifard V, Shirzadi E, Samandari S, Afshar H, Maracy MR. Memantine add on to citalopram in elderly patients with depression: a double-blind placebo-controlled study. J Res Med Sci. 2014;19(6):525\u201330. There was no difference in efficacy for geriatric depression between the citalopram plus memantine group and the citalopram plus placebo group","journal-title":"J Res Med Sci"},{"issue":"6","key":"899_CR34","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1192\/bjp.bp.114.145177","volume":"205","author":"OP Almeida","year":"2014","unstructured":"Almeida OP, Ford AH, Hirani V, Singh V, vanBockxmeer FM, McCaul K, et al. B vitamins to enhance treatment response to antidepressants in middle-aged and older adults: results from the B-VITAGE randomised, double-blind, placebo-controlled trial. Br J Psychiatry. 2014;205(6):450\u20137.","journal-title":"Br J Psychiatry"},{"key":"899_CR35","doi-asserted-by":"crossref","unstructured":"Alexopoulos GS, Katz IR, Reynolds CF 3rd, Carpenter D, Docherty JP, Ross RW. Pharmacotherapy of depression in older patients: a summary of the expert consensus guidelines. J Psychiatr Pract. 2001;7(6):361\u201376.","DOI":"10.1097\/00131746-200111000-00003"},{"key":"899_CR36","unstructured":"FDA. Drug Safety Announcement Posted 3\/28\/2012. Accessed 11\/12\/2017; https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm297391.htm ."},{"issue":"9","key":"899_CR37","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1002\/gps.424","volume":"16","author":"DC Steffens","year":"2001","unstructured":"Steffens DC, Doraiswamy PM, McQuoid DR. Bupropion SR in the naturalistic treatment of elderly patients with major depression. Int J Geriatr Psychiatry. 2001;16(9):862\u20135.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"2\u20133","key":"899_CR38","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jad.2012.02.036","volume":"141","author":"RM Kok","year":"2012","unstructured":"Kok RM, Nolen WA, Heeren TJ. Efficacy of treatment in older depressed patients: a systematic review and meta-analysis of double-blind randomized controlled trials with antidepressants. J Affect Disord. 2012;141(2\u20133):103\u201315.","journal-title":"J Affect Disord"},{"issue":"10","key":"899_CR39","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1001\/jamapsychiatry.2015.1324","volume":"72","author":"SF Smagula","year":"2015","unstructured":"Smagula SF, Butters MA, Anderson SJ, Lenze EJ, Dew MA, Mulsant BH, et al. Antidepressant response trajectories and associated clinical prognostic factors among older adults. JAMA psychiatry. 2015;72(10):1021\u20138.","journal-title":"JAMA psychiatry"},{"issue":"9","key":"899_CR40","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1177\/0706743716659276","volume":"61","author":"GM MacQueen","year":"2016","unstructured":"MacQueen GM, Frey BN, Ismail Z, et al. Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 6. Special populations: youth, women, and the elderly. Can J Psychiatr. 2016;61(9):588\u2013603.","journal-title":"Can J Psychiatr"},{"issue":"10","key":"899_CR41","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jagp.2016.05.010","volume":"24","author":"K Arandjelovic","year":"2016","unstructured":"Arandjelovic K, Eyre HA, Lavretsky H. Clinicians\u2019 views on treatment-resistant depression: 2016 survey reports. Am J Geriatr Psychiatry. 2016;24(10):913\u20137.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"10","key":"899_CR42","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.jagp.2013.01.030","volume":"21","author":"DT Maust","year":"2013","unstructured":"Maust DT, Oslin DW, Thase ME. Going beyond antidepressant monotherapy for incomplete response in nonpsychotic late-life depression: a critical review. Am J Geriatr Psychiatry. 2013;21(10):973\u201386.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"9","key":"899_CR43","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/gps.2813","volume":"27","author":"EJ Lenze","year":"2012","unstructured":"Lenze EJ, Skidmore ER, Begley AE, Newcomer JW, Butters MA, Whyte EM. Memantine for late-life depression and apathy after a disabling medical event: a 12-week, double-blind placebo-controlled pilot study. Int. J. Geriatr. Psychiatry. 2012;27(9):974\u201380.","journal-title":"Int. J. Geriatr. Psychiatry."},{"issue":"3","key":"899_CR44","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.cger.2014.05.002","volume":"30","author":"BH Mulsant","year":"2014","unstructured":"Mulsant BH, Blumberger DM, Ismail Z, Rabheru K, Rapoport MJ. A systematic approach to pharmacotherapy for geriatric major depression. Clin Geriatr Med. 2014;30(3):517\u201334.","journal-title":"Clin Geriatr Med"},{"issue":"7","key":"899_CR45","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/01.JGP.0000308883.64832.ed","volume":"16","author":"JC Nelson","year":"2008","unstructured":"Nelson JC, Delucchi K, Schneider LS. Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence. Am J Geriatr Psychiatry. 2008;16(7):558\u201367.","journal-title":"Am J Geriatr Psychiatry"},{"key":"899_CR46","doi-asserted-by":"crossref","unstructured":"Small GW, Hamilton SH, Bystritsky A, Meyers BS, Nemeroff CB. Clinical response predictors in a double-blind, placebo-controlled trial of fluoxetine for geriatric major depression. Fluoxetine Collaborative Study Group. Int Psychogeriatr 1995;7 Suppl:41\u201353, 7.","DOI":"10.1017\/S1041610295002341"},{"issue":"6","key":"899_CR47","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/0006-3223(87)90205-8","volume":"22","author":"A Georgotas","year":"1987","unstructured":"Georgotas A, McCue RE, Cooper T, Chang I, Mir P, Welkowitz J. Clinical predictors of response to antidepressants in elderly patients. Biol Psychiatry. 1987;22(6):733\u201340.","journal-title":"Biol Psychiatry"},{"issue":"10","key":"899_CR48","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/gps.1779","volume":"22","author":"JC Nelson","year":"2007","unstructured":"Nelson JC, Holden K, Roose S, Salzman C, Hollander SB, Betzel JV. Are there predictors of outcome in depressed elderly nursing home residents during treatment with mirtazapine orally disintegrating tablets? Int. J. Geriatr. Psychiatry. 2007;22(10):999\u20131003.","journal-title":"Int. J. Geriatr. Psychiatry."},{"issue":"7","key":"899_CR49","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1185\/03007995.2014.904770","volume":"30","author":"O Dolberg","year":"2014","unstructured":"Dolberg O, Larsson Lonn S, Kvist K. Factors predicting relapse in elderly patients with major depressive disorder treated with escitalopram in an outpatient setting. Curr Med Res Opin. 2014;30(7):1301\u20137.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"899_CR50","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/JGP.0b013e31817b60af","volume":"17","author":"HJ Aizenstein","year":"2009","unstructured":"Aizenstein HJ, Butters MA, Wu M, Mazurkewicz LM, Stenger VA, Gianaros PJ, et al. Altered functioning of the executive control circuit in late-life depression: episodic and persistent phenomena. Am J Geriatr Psychiatry. 2009;17(1):30\u201342.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"8","key":"899_CR51","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/gps.1988","volume":"23","author":"GS Alexopoulos","year":"2008","unstructured":"Alexopoulos GS, Raue PJ, Kanellopoulos D, Mackin S, Arean PA. Problem solving therapy for the depression-executive dysfunction syndrome of late life. Int. J. Geriatr. Psychiatry. 2008;23(8):782\u20138.","journal-title":"Int. J. Geriatr. Psychiatry."},{"issue":"5","key":"899_CR52","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/gps.2743","volume":"27","author":"SS Morimoto","year":"2012","unstructured":"Morimoto SS, Gunning FM, Kanellopoulos D, Murphy CF, Klimstra SA, Kelly RE Jr, et al. Semantic organizational strategy predicts verbal memory and remission rate of geriatric depression. Int. J. Geriatr. Psychiatry. 2012;27(5):506\u201312.","journal-title":"Int. J. Geriatr. Psychiatry."},{"issue":"14","key":"899_CR53","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1017\/S0033291715001075","volume":"45","author":"GS Alexopoulos","year":"2015","unstructured":"\u2022 Alexopoulos GS, Manning K, Kanellopoulos D, McGovern A, Seirup JK, Banerjee S, et al. Cognitive control, reward-related decision making and outcomes of late-life depression treated with an antidepressant. Psychol Med. 2015;45(14):3111\u201320. Study of cognitive dysfunction in LLD suggesting that differentiating types of cognitive impairment may identify treatment responsiveness.","journal-title":"Psychol Med"},{"issue":"6","key":"899_CR54","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1017\/S0033291711002133","volume":"42","author":"AY Dombrovski","year":"2012","unstructured":"Dombrovski AY, Siegle GJ, Szanto K, Clark L, Reynolds CF, Aizenstein H. The temptation of suicide: striatal gray matter, discounting of delayed rewards, and suicide attempts in late-life depression. Psychol Med. 2012;42(6):1203\u201315.","journal-title":"Psychol Med"},{"issue":"4","key":"899_CR55","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1001\/jamapsychiatry.2015.3447","volume":"73","author":"SH Kaneriya","year":"2016","unstructured":"\u2022 Kaneriya SH, Robbins-Welty GA, Smagula SF, Karp JF, Butters MA, Lenze EJ, et al. Predictors and moderators of remission with aripiprazole augmentation in treatment-resistant late-life depression: an analysis of the IRL-GRey randomized clinical trial. JAMA Psychiatry. 2016;73(4):329\u201336. Post-hoc analysis of LLD treatment response to pharmacotherapy based on neurocognitive testing.","journal-title":"JAMA Psychiatry"},{"key":"899_CR56","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jpsychires.2016.07.005","volume":"81","author":"SF Smagula","year":"2016","unstructured":"Smagula SF, Wallace ML, Anderson SJ, Karp JF, Lenze EJ, Mulsant BH, et al. Combining moderators to identify clinical profiles of patients who will, and will not, benefit from aripiprazole augmentation for treatment resistant late-life major depressive disorder. J Psychiatr Res. 2016;81:112\u20138.","journal-title":"J Psychiatr Res"},{"issue":"5","key":"899_CR57","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jagp.2013.11.005","volume":"23","author":"KJ Manning","year":"2015","unstructured":"Manning KJ, Alexopoulos GS, Banerjee S, Morimoto SS, Seirup JK, Klimstra SA, et al. Executive functioning complaints and escitalopram treatment response in late-life depression. Am J Geriatr Psychiatry. 2015;23(5):440\u20135.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"6","key":"899_CR58","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jagp.2017.02.006","volume":"25","author":"LW Victoria","year":"2017","unstructured":"Victoria LW, Whyte EM, Butters MA, Meyers BS, Alexopoulos GS, Mulsant BH, et al. Improvement in depression is associated with improvement in cognition in late-life psychotic depression. Am J Geriatr Psychiatry. 2017;25(6):672\u20139.","journal-title":"Am J Geriatr Psychiatry"},{"key":"899_CR59","doi-asserted-by":"crossref","unstructured":"\u2022 Joel I, Begley AE, Mulsant BH, Lenze EJ, Mazumdar S, Dew MA, et al. Dynamic prediction of treatment response in late-life depression. Am J Geriatr Psychiatry. 2014;22(2):167\u201376. Study looked at predictors of treatment response in LLD with suggested recommendations for making decisions to continue or change therapy based on these factors.","DOI":"10.1016\/j.jagp.2012.07.002"},{"issue":"7","key":"899_CR60","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1176\/appi.ajp.2008.07081340","volume":"165","author":"C Andreescu","year":"2008","unstructured":"Andreescu C, Mulsant BH, Houck PR, Whyte EM, Mazumdar S, Dombrovski AY, et al. Empirically derived decision trees for the treatment of late-life depression. Am J Psychiatry. 2008;165(7):855\u201362.","journal-title":"Am J Psychiatry"},{"issue":"6","key":"899_CR61","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/14656566.2017.1308484","volume":"18","author":"K Patel","year":"2017","unstructured":"Patel K, Abdool PS, Rajji TK, Mulsant BH. Pharmacotherapy of major depression in late life: what is the role of new agents? Expert Opin Pharmacother. 2017;18(6):599\u2013609.","journal-title":"Expert Opin Pharmacother"},{"issue":"17","key":"899_CR62","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1080\/14656566.2016.1254188","volume":"17","author":"JL Beyer","year":"2016","unstructured":"Beyer JL, Weisler RH. Adjunctive brexpiprazole for the treatment of major depressive disorder. Expert Opin Pharmacother. 2016;17(17):2331\u20139.","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"899_CR63","doi-asserted-by":"publisher","first-page":"247","DOI":"10.4088\/JCP.13m08852","volume":"76","author":"LB Wan","year":"2015","unstructured":"Wan LB, Levitch CF, Perez AM, Brallier JW, Iosifescu DV, Chang LC, et al. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. 2015;76(3):247\u201352.","journal-title":"J Clin Psychiatry"}],"container-title":["Current Psychiatry Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11920-018-0899-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-018-0899-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-018-0899-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T14:42:52Z","timestamp":1660833772000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11920-018-0899-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,7]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["899"],"URL":"https:\/\/doi.org\/10.1007\/s11920-018-0899-6","relation":{},"ISSN":["1523-3812","1535-1645"],"issn-type":[{"value":"1523-3812","type":"print"},{"value":"1535-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,7]]},"assertion":[{"value":"7 April 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Kim G. Johnson declares no conflict of interest. John L. Beyer has received grants from Allergan, Forest, Janssen, Takeda, and Sunovion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"34"}}